 |
Molika Ashford is a GenomeWeb contributing editor and covers personalized medicine and molecular diagnostics. E-mail Molika Ashford. |
Prospective Validation Confirms Sensitivity of Veracyte's Gene Expression Test for Thyroid Nodule Risk
June 27, 2012
Prospective Validation Confirms Sensitivity of Veracyte's Gene Expression Test for Thyroid Nodule Risk
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Multi-institutional GWAS IDs Variant to Improve Warfarin Dosing in People of African Descent
June 12, 2013 / Pharmacogenomics Reporter - Prostate Cancer Risk Markers Show Promise for Test to ID Elevated Risk in Men with Benign Hyperplasia
April 3, 2013 / Pharmacogenomics Reporter - Prospective Study Suggests Site-Specific Treatment after BioTheranostics' CUP Testing Improves Survival
October 17, 2012 / Pharmacogenomics Reporter - CardioDx Says $58M Financing Will Support Commercial Expansion Following Medicare Coverage Win
August 29, 2012 / Pharmacogenomics Reporter - Myriad Presents Fourth Study Showing Prolaris Score Predicts Prostate Cancer Aggressiveness
February 8, 2012 / Pharmacogenomics Reporter